As the usage of GLP-1 medications continues to grow, life and health insurance sectors are starting to explore their potential effects on underwriting practices. Although the landscape is still developing, according to Neil Sprackling (pictured), CEO, life and health US, Swiss Re, early indications suggest that GLP-1 drugs could favourably impact risk assessments. This evolving understanding may prompt insurers to rethink how these medications are integrated into policy pricing and risk evaluation.
